BioSpace News Archive

Millennium Dental Technologies, Inc., announces limited-time dynamic pricing on the PerioLase® Periodontal Package™ for the LANAP® protocol, LAPIP™ protocol, and VAPs™.

Leap Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2019 .

AVROBIO reports fourth quarter and fiscal year 2019 results

RESEARCH TRIANGLE PARK, N.C., March 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p<0.001) compared to placebo, and reduced the number of HAE attacks requiring acute SoC treatment by 49.2 percent (p<0.001) comp

March 16, 2020 11:00 UTC Company on track to complete Vicinium ® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year

An increasing number of patients and providers are turning to the transcranial magnetic stimulation (TMS) market leader as a proven, non-drug treatment option for depression

- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours - Test kit to be made available via Curetis’ European sales channels

Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the quarter and year ended December 31, 2019, as well as recent business highlights.